Immunoprecise Antibodies Stock Operating Margin
| HYFT Stock | 1.87 0.26 16.15% |
ImmunoPrecise Antibodies' fundamental analysis aims to assess its intrinsic value by examining key economic and financial indicators - such as cash flow records, changes in balance sheet accounts, income statement trends, financial ratios, and relevant microeconomic factors affecting ImmunoPrecise Stock price.
| Last Reported | Projected for Next Year | ||
| Operating Profit Margin | (0.50) | (0.02) |
ImmunoPrecise | Operating Margin | Build AI portfolio with ImmunoPrecise Stock |
ImmunoPrecise Antibodies Company Operating Margin Analysis
ImmunoPrecise Antibodies' Operating Margin shows how much operating income a company makes on each dollar of sales. It is one of the profitability indicators which helps analysts to understand whether the firm is successful or not making money from everyday operations.
Current ImmunoPrecise Antibodies Operating Margin | -0.0211 |
Most of ImmunoPrecise Antibodies' fundamental indicators, such as Operating Margin, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, ImmunoPrecise Antibodies is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
ImmunoPrecise Operating Margin Driver Correlations
Understanding the fundamental principles of building solid financial models for ImmunoPrecise Antibodies is extremely important. It helps to project a fair market value of ImmunoPrecise Stock properly, considering its historical fundamentals such as Operating Margin. Since ImmunoPrecise Antibodies' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of ImmunoPrecise Antibodies' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of ImmunoPrecise Antibodies' interrelated accounts and indicators.
Click cells to compare fundamentals
A good Operating Margin is required for a company to be able to pay for its fixed costs or payout its debt, which implies that the higher the margin, the better. This ratio is most effective in evaluating the earning potential of a company over time when comparing it against a firm's competitors.
| Competition |
ImmunoPrecise Pretax Profit Margin
Pretax Profit Margin |
|
ImmunoPrecise Operating Margin Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses ImmunoPrecise Antibodies' direct or indirect competition against its Operating Margin to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of ImmunoPrecise Antibodies could also be used in its relative valuation, which is a method of valuing ImmunoPrecise Antibodies by comparing valuation metrics of similar companies.ImmunoPrecise Antibodies is currently under evaluation in operating margin category among its peers.
ImmunoPrecise Antibodies Current Valuation Drivers
We derive many important indicators used in calculating different scores of ImmunoPrecise Antibodies from analyzing ImmunoPrecise Antibodies' financial statements. These drivers represent accounts that assess ImmunoPrecise Antibodies' ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of ImmunoPrecise Antibodies' important valuation drivers and their relationship over time.
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 (projected) | ||
| Market Cap | 52.8M | 197.4M | 140.7M | 86.8M | 45.2M | 20.2M | |
| Enterprise Value | 54.7M | 159.1M | 113.3M | 85.7M | 55.4M | 22.9M |
ImmunoPrecise Fundamentals
| Revenue | 24.52 M | |||
| EBITDA | (28.86 M) | |||
| Net Income | (30.23 M) | |||
| Total Debt | 13.4 M | |||
| Cash Flow From Operations | (6.41 M) | |||
| Number Of Employees | 81 | |||
| Total Asset | 44.44 M | |||
| Retained Earnings | (128.79 M) | |||
| Working Capital | 9.74 M | |||
| Net Asset | 44.44 M |
About ImmunoPrecise Antibodies Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze ImmunoPrecise Antibodies's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of ImmunoPrecise Antibodies using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of ImmunoPrecise Antibodies based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for ImmunoPrecise Stock Analysis
When running ImmunoPrecise Antibodies' price analysis, check to measure ImmunoPrecise Antibodies' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy ImmunoPrecise Antibodies is operating at the current time. Most of ImmunoPrecise Antibodies' value examination focuses on studying past and present price action to predict the probability of ImmunoPrecise Antibodies' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move ImmunoPrecise Antibodies' price. Additionally, you may evaluate how the addition of ImmunoPrecise Antibodies to your portfolios can decrease your overall portfolio volatility.